BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 24, 2008
View Archived Issues
Novartis reviews recent highlights
Read More
New compounds for neurological disorders disclosed in recent patents
Read More
Recent patents describe new agents for endocrine-related disorders
Read More
Gilead initiates enrollment in phase III clinical trial of integrase inhibitor elvitegravir in HIV
Read More
Roche gives up rights to license voclosporin for solid organ transplant
Read More
Japanese Ministry of Health, Labor and Welfare grants approval to Ikaria's INOflo
Read More
Sunitinib under preclinical development for head and neck squamous cell carcinoma
Read More
Metronomic therapy with novel Bcl-2 inhibitor and cisplatin shows benefit in head and neck cancer
Read More
JSI-124 enhances activity of cisplatin against resistant head and neck carcinoma
Read More
Sanofi-aventis begins phase III studies with AVE-0010 for the treatment of type 2 diabetes
Read More
SkyePharma reports positive results from two phase III clinical studies of Flutiform
Read More
Merck profiles highlights of second quarter
Read More
FDA yet to make decision regarding Theravance's NDA for telavancin in cSSSI
Read More
Protherics presents update on company's activities
Read More
Hyperion completes enrollment in phase I/II clinical trial of HPN-100 vs. Buphenyl in UCD
Read More
CeNeRx to initiate phase II trial of Tyrima in depression in third quarter of 2008
Read More
Xanodyne receives approvable letter from FDA for pain treatment Zipsor
Read More
RNAi against PrPc reduces neurodegeneration and extends survival in murine prion disease
Read More
Optimer completes enrollment in phase III OPT-80 trial in C. difficile infection
Read More
Bristol-Myers Squibb and AstraZeneca submit NDA and MAA for Onglyza
Read More
